Scientific Survey
The number of people affected with diabetes is almost reaching 425 million. Despite the availability of diverse therapies, many patients are unable to reach their desired glycaemic targets.
Insulin remains the main stay of treatment for all type 1DM and for those type 2 DM who are uncontrolled with OADs. Early initiation of insulin is known to reduce the risk the complications and overall mortality amongst people living with Diabetes. Health care expenditure in India is mainly out of pocket. Diabetes being a chronic condition, may lead to financial burden on them. Apart from injection fear, the most common reason for late initiation and poor adherence is the cost of insulin treatment.
Biosimilars have come as a boon in this steeping inflating cost of original insulin. It provides access to high-quality, affordable biologic therapy that is otherwise inaccessible due to high cost. Biosimilars have comparable structural and analytical characterization to the original biologics with NO clinically significant or meaningful differences in efficacy or safety.
Biocon’ Insulin Glargine has been approved by US FDA as the first INTERCHANGEABLE biosimilar insulin, indicated to improve glycaemic control in adults and paediatric patients with Type 1 diabetes mellitus and in adults with Type 2 diabetes mellitus.
This interchangeable insulin glargine provides patients with a safe, high-quality and cost-effective option for treating diabetes.
This survey is intended to compare the efficacy and safety as well as gather opinions from renowned doctors regarding the selection of Insulin Glargine for best treatment outcomes in patients with diabetes mellitus.
The objective of the Survey:
1. To derive an unbiased approach in decision making and appropriate selection of insulin regimen.
2. To collect unbiased valuable feedback from well-known HCPs.
The derived feedback shall enable us to compare the results of the various insulin regimens for the best treatment outcomes.